Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamiparib - BeiGene

Next Previous
Drug Profile

Pamiparib - BeiGene

Alternative Names: BeiGene-290; BGB-290; BGB-290-BeiGene; PARPi - BeiGene

Latest Information Update: 17 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Merck Serono; National Cancer Institute (USA); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer; Fallopian tube cancer; Gastric cancer; Ovarian cancer
  • Phase II Breast cancer; Prostate cancer
  • Phase I/II Glioblastoma; Glioma; Solid tumours
  • No development reported Peritoneal cancer

Most Recent Events

  • 03 Jan 2020 Phase-I/II clinical trials in Glioma (Recurrent, Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03914742)
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO)
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Peritoneal-cancer(Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top